Chronic Lymphocytic Leukemia

Hoffman Explores Frontline Treatments in CLL

July 27, 2020

Marc Hoffman, MD, reviewed a case of a 61-year-old man with chronic lymphocytic leukemia, during a virtual Case Based Peer Perspectives event.

Danilov Discusses Therapies for Relapsed/Refractory CLL

July 26, 2020

Alexey Danilov, MD, PhD, discussed the case of 71-year-old woman with relapsed/refractory chronic lymphocytic leukemia during a virtual Case Based Peer Perspectives event.

A 79-Year-Old Man With Relapsed Chronic Lymphocytic Leukemia

July 20, 2020

Jeff Sharman, MD, reviews a case of a 79-year-old man with relapsed chronic lymphocytic leukemia.

Long-Term Results of Ibrutinib/Umbralisib Show Efficacy in CLL and MCL

July 06, 2020

Matthew S. Davids, MD, discusses the long-term follow-up of a phase 1/1b trial for patients with relapsed/refractory chronic lymphocytic leukemia or mantle cell lymphoma receiving ibrutinib and umbralisib.

Duvelisib May Improve Health-Related QoL in Relapsed or Refractory CLL and SLL

July 02, 2020

In the phase 3 DUO clinical trial, treatment with duvelisib improved health-related quality of life in patients with relapsed or refractory chronic lymphocytic leukemia compared with ofatumumab.

FDA Grants Orphan Drug Designation to Cirmtuzumab in MCL and CLL

June 30, 2020

"We are excited about cirmtuzumab’s potential for the treatment of patients with ROR1-expressing cancers, including mantle cell lymphoma, chronic lymphocytic leukemia, HER2-negative breast cancer, and other solid tumors, and look forward to further advancing its development to benefit patients with significant unmet medical needs."

Discontinuation of Venetoclax Impacts Outcomes of Rituximab Combination in CLL

June 25, 2020

In an interview with Targeted Oncology, Anthony Mato, MD, discussed the findings of venetoclax interruptions or discontinuations observed in patients with relapsed/refractory chronic lymphocytic leukemia who received the combination of venetoclax plus rituximab in the phase 3 MURANO study.

Complex Karyotype Strongly Associated With Shorter PFS in Chronic Lymphocytic Leukemia

June 25, 2020

All patients with relapsed/refractory chronic lymphocytic leukemia should be evaluated for both complex karyotypes and del17p prior to initiating treatment, and all patients with complex karyotypes should be considered candidates for alternative combination therapy.

Doctors Debate: Is Chemoimmunotherapy or Small Molecule Inhibition Most Optimal for Frontline Treatment of CLL?

June 18, 2020

During a debate made available as part of the 2020 National Comprehensive Cancer Network Virtual Annual Conference, Deborah Stephens, DO, and Mazyar Shadman, MD, MPH, discussed the most optimal frontline therapy for chronic lymphocytic leukemia.

Interim Data of Cirmtuzumab and Ibrutinib Show Efficacy in MCL and CLL

June 12, 2020

Hun Ju Lee, MD, discusses the clinical activity of cirmtuzumab, an anti-ROR1 antibody, in combination with ibrutinib in a phase 1b/2 study of patients with mantle cell lymphoma or chronic lymphocytic leukemia.